NYSE:USNA - USANA Health Sciences Stock Price, News, & Analysis

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences announced that its board has authorized a share buyback program on Tuesday, October 23rd 2018, which permits the company to buyback $150,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 5.9% of its shares through open market purchases. Shares buyback programs are often a sign that the company's management believes its stock is undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings results on Tuesday, February, 5th. The company reported $1.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.33 by $0.01. The company earned $299.02 million during the quarter, compared to analysts' expectations of $305.79 million. USANA Health Sciences had a return on equity of 29.94% and a net margin of 10.61%. The business's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.11 EPS. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences updated its FY19 earnings guidance on Tuesday, February, 5th. The company provided earnings per share guidance of $5.25-5.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.86. The company issued revenue guidance of $1.25-1.30 billion, compared to the consensus revenue estimate of $1.31 billion.

2 brokerages have issued 1 year price targets for USANA Health Sciences' stock. Their forecasts range from $135.00 to $135.00. On average, they expect USANA Health Sciences' stock price to reach $135.00 in the next twelve months. This suggests a possible upside of 35.7% from the stock's current price. View Analyst Price Targets for USANA Health Sciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for USANA Health Sciences.

News stories about USNA stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. USANA Health Sciences earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.

Some companies that are related to USANA Health Sciences include Tilray (TLRY), Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), Cronos Group (CRON), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Canopy Rivers (RIV), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), China Jo-Jo Drugstores (CJJD), Mannatech (MTEX), GLG Life Tech (GLGLF), Cyanotech (CYAN) and FitLife Brands (FTLF).

USANA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.54%), Acadian Asset Management LLC (3.58%), Dimensional Fund Advisors LP (2.62%), Prudential Financial Inc. (1.04%), Robeco Institutional Asset Management B.V. (0.99%) and MERIAN GLOBAL INVESTORS UK Ltd (0.98%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Fort L.P., Millennium Management LLC, Two Sigma Investments LP, Prudential Financial Inc., Bank of New York Mellon Corp, Acadian Asset Management LLC and Mackay Shields LLC. Company insiders that have sold USANA Health Sciences company stock in the last year include Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

USNA stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Nordea Investment Management AB, First Trust Advisors LP, APG Asset Management N.V., Burney Co., Bank of America Corp DE, BlackRock Inc. and Martingale Asset Management L P. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull and Myron W Wentz. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $99.47.

USANA Health Sciences has a market capitalization of $2.38 billion and generates $1.19 billion in revenue each year. The company earns $126.22 million in net income (profit) each year or $5.16 on an earnings per share basis. USANA Health Sciences employs 1,810 workers across the globe.

The official website for USANA Health Sciences is http://www.usana.com.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]